The cost-utility of Magnetic Resonance Imaging for breast cancer in BRCA1 mutation carriers aged 30-49
- Publication Type:
- Journal Article
- European Journal of Health Economics, 2007, 8 (2), pp. 137 - 144
- Issue Date:
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Recent evidence has investigated the costeffectiveness of magnetic resonance imaging (MRI) in younger women with a BRCA1 mutation. However, this evidence has not been contrasted with existing cost-effectiveness standards to determine whether screening is appropriate, given limited societal resources. We constructed a Markov model investigating surveillance tools (mammography, MRI, both in parallel) under a National Health Service (NHS) perspective. The key benefit of MRI is that increased sensitivity leads to early detection, and improved prognosis. For a 30- to 39-year-old cohort, the cost per quality-adjusted life year (QALY) of mammography relative to no screening was £5,200. The addition of MRI to this costs £13,486 per QALY. For a 40- to 49- year-old cohort, the corresponding values were £2,913 and £7,781. Probabilistic sensitivity analysis supported the cost-effectiveness of the parallel approach of mammography and MRI. It is necessary to extend this analysis beyond BRCA1 carriers within this age group, and also to other age groups.
Please use this identifier to cite or link to this item: